Shares of Moderna Inc.
gained 5.9% in trading on Tuesday after research correspondence published in The New England Journal of Medicine indicates that the company’s COVID-19 vaccine generated antibodies that extend at least six months after the second dose among a small group of study participants. This is based on tracking COVID-19 antibodies in 33 participants in the Phase 1 clinical trial, which is still ongoing. This is a similar finding to data recently released about immune response to BioNTech SE
and Pfizer Inc.’s
mRNA vaccine. “Our data show antibody persistence,” the researchers wrote in the letter, which published Tuesday. At this time it is unknown how long the vaccines protect people who have been immunized. Shares of Moderna have gained 17.5% since the start of the year, while the broader S&P 500
is up 8.6%.
This is not a CAPTIS article. Originally, it was published here.